Bicycle Therapeutics PLC
BCYC
View Detailed Chart
5.660USD
+0.350+6.59%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
282.26MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.59%
5 Days
-11.84%
1 Month
-13.85%
6 Months
-25.13%
Year to Date
-20.06%
1 Year
-55.11%
View Detailed Chart
TradingKey Stock Score of Bicycle Therapeutics PLC
Currency: USD Updated: 2026-02-06Key Insights
Bicycle Therapeutics PLC's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.17.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bicycle Therapeutics PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Bicycle Therapeutics PLC Highlights
StrengthsRisks
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 35.27M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 35.27M.
Overvalued
The company’s latest PE is -1.56, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 39.22M shares, increasing 0.08% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 10.52K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
20.167
Target Price
+279.79%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bicycle Therapeutics PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Bicycle Therapeutics PLC Info
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Ticker SymbolBCYC
CompanyBicycle Therapeutics PLC
CEOLee (Kevin)
Websitehttps://www.bicycletherapeutics.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69275.500
-694.630 (-0.99%)
282.580
+22.390 (+8.61%)
2051.040
-0.690 (-0.03%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
